uniQure stock jumped 5.3% to US$42.19 after its Q2 release, a sharp move for a gene therapy developer that is still posting deep losses. The headlines are not about earnings beats. The story is about whether the cash and pipeline can carry the company across a long and expensive bridge to potential commercial launches.

The quarter showed another heavy quarterly loss with basic earnings per share of US$1.22 in the red and revenue of just US$5.8m. The key focus now is the balance sheet. Management reports about US$810.3m in cash and investments and indicates that this funding runway extends into 2030.

Love the cash runway at uniQure but concerned about ongoing losses and limited current revenue? Take a look at our 89 resilient stocks with low risk scores for companies that pair stronger balance sheets with lower risk profiles.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$5.84m vs. US$5.26m (small year on year increase)
• Net Loss (Q2 2026 vs. Q2 2025): US$81.06m loss vs. US$37.72m loss (loss widened)
• Basic EPS (Q2 2026 vs. Q2 2025): US$1.22 loss per share vs. US$0.69 loss per share (loss per share widened)
• Products in Phase I (Q2 2026 vs. Q2 2025): 4 vs. 4 (pipeline breadth at this stage unchanged)

Tired of squinting at rows of Q2 numbers and cash runway figures for uniQure? Get a clear visual snapshot of the company’s balance sheet strength and overall financial picture in the company report for uniQure.

uniQure bull case hinges on AMT-130 and cash

The optimistic view is that AMT-130 can move from promising data and FDA designations into an actual commercial product, with uniQure’s enlarged cash pile giving enough time to get there. This quarter supports parts of that story. FDA Type B minutes confirm that 3 year Phase I/II data are an acceptable primary basis for an accelerated approval filing, and that a sham control is no longer required in the confirmatory trial. A Q3 2026 BLA and U.K. MAA are still the anchor milestones, and management reiterated that timing. Cash and investments of about US$810.3m, up from US$622.5m at year end, back the claim of runway into 2030. Early AMT-260 and AMT-191 readouts add some optionality, although both still carry clear safety and data gating steps.

Bear case focuses on losses, dependency and risk

The sceptical view is that uniQure is burning cash on a single lead program while reporting limited revenue, with clinical and regulatory risk still high. Q2 numbers give that view real support. Revenue sits at US$5.8m while the company recorded a net loss of US$81.06m and basic EPS loss of US$1.22. SG&A rose to US$17.4m as commercial hiring ramps ahead of any approval, which increases fixed cost before there is product income. The story remains heavily tied to AMT-130. FDA wants the global confirmatory trial design agreed before BLA submission and expects it to be feasible to complete in a reasonable timeframe, which creates execution pressure. AMT-191 dosing pauses after Grade 3 liver function test elevations underline that safety management for systemic gene therapy is still an open issue.

Compare uniQure’s internal story about AMT-130 progress and cash runway with how the stock’s 5.3% post earnings move lines up against institutional expectations. See the consensus price target analysis for uniQure to check whether Wall Street targets are keeping pace with the latest Q2 narrative.

Stay Ahead With Simply Wall St

If uniQure’s cash runway and AMT-130 milestones have your attention, register for free with Simply Wall St and add the stock to a Watchlist to track price against fair value and watch how the story develops. Once you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on key updates that matter to your holdings. For a broader view on sentiment and ideas, tap into crowd insights through the Community and see how other investors are thinking about opportunities and risks. This combination can help surface potential catalysts and possible red flags earlier so you can respond more quickly to new information.

Curious To Explore Alternatives Beyond uniQure

Fresh stock ideas can start to break out while most investors stay focused on yesterday’s headlines. Spot momentum under the radar for now and consider acting before the crowd. Get in early.

• Spot potential compounding machines with strong cash generation and sensible balance sheets by scanning the curated 56 high quality undervalued stocks before the best entry points are identified by momentum traders.
• Consider the structural shift toward automation by reviewing hand picked 34 robotics and automation stocks that could benefit as demand builds, while these stories are still flying under most radars.
• Review possible infrastructure upgrades by checking the targeted 35 power grid technology and infrastructure stocks and weigh which businesses look best placed before sentiment shifts and prices start moving.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.